Clinical trials: Resectable Pancreatic Adenocarcinoma
Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being…
- Trial name
- PaTK02 (NCT02446093)
- Testing
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy
- Where
- 3 sites in United States, Mexico
- Volunteers
- 54 people
- Sponsor
- Candel Therapeutics, Inc.